KLBF:IDX
Kalbe Farma Tbk PT
IDRÂ 760.00
arrow_downward
-2.56%(-20.00) 1D
Sep 9, 4:10:30 PM GMT+7 · IDR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KLBF...
Open
IDRÂ 780
High
IDRÂ 785
Low
IDRÂ 760
Mkt. cap
35.58T
Avg. vol.
85.55M
Volume
117.41M
Dividend
2.63%
Quarterly dividend
IDRÂ 5
Ex-dividend date
Jun 4, 2026
P/E ratio
9.55
52-wk high
IDRÂ 1,345
52-wk low
IDRÂ 630
EPS
IDRÂ 80
Shares outstanding
46.81B
No. of employees
13K
Open
IDRÂ 780
High
IDRÂ 785
Low
IDRÂ 760
Mkt. cap
35.58T
Avg. vol.
85.55M
Volume
117.41M
Dividend
2.63%
Quarterly dividend
IDRÂ 5
Ex-dividend date
Jun 4, 2026
P/E ratio
9.55
52-wk high
IDRÂ 1,345
52-wk low
IDRÂ 630
EPS
IDRÂ 80
Shares outstanding
46.81B
No. of employees
13K
Profile
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
About Kalbe Farma Tbk PT